Protagonist Therapeutics (Nasdaq: PTGX) granted stock-based inducement awards on June 30, 2026 to three new employees under its Inducement Plan. Awards include options for 8,650 shares and 2,275 RSUs at an exercise price of $122.58 per share.
Options vest over four years, with 25% after one year and the rest monthly over three years. RSUs vest in four equal annual installments. The compensation committee approved these grants as material inducements under Nasdaq Rule 5635(c)(4).
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – PTGX
+5.15%
+5.15%News Effect
On the day this news was published, PTGX gained 5.15%, reflecting a notable positive market reaction.
The stock moved +5.2% in the session following this news. A strong positive reaction aligns with PTG...
Analysis
The stock moved +5.2% in the session following this news. A strong positive reaction aligns with PTGX’s history of share moves tracking news tone and comes as the stock trades near its 52-week high. Elevated short positioning could amplify upside but also increase reversal risk if sentiment cools.
Key Figures
Stock options granted:8,650 sharesRSUs granted:2,275 sharesOption exercise price:$122.58+5 more
8 metrics
Stock options granted8,650 sharesAggregate inducement options to three new employees on June 30, 2026
RSUs granted2,275 sharesAggregate inducement RSUs to three new employees on June 30, 2026
Option exercise price$122.58Equal to PTGX June 30, 2026 Nasdaq Global Market closing price
Option vesting period4 years25% after first anniversary of hire, remainder monthly over three years
RSU vesting schedule1/4 annually over 4 yearsTime-based vesting of inducement RSUs
Inducement plan adoptionMay 29, 2018Original adoption date of Amended and Restated Inducement Plan
Plan amendment datesFeb 18, 2020; Feb 15, 2022Amendment history of the inducement plan
Current share price$122.58Pre-news price, ~3% below 52-week high of $126.59
Exercise of U.S. opt-out right for rusfertide with large milestone potential.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent PTGX news has generally seen share moves align with the perceived tone of the announcements, except for one negative reaction to clinical presentation news.
Key Terms
restricted stock units (rsus), nasdaq global market, exercise price
3 terms
restricted stock units (rsus)financial
"The new employees received, in the aggregate, options to purchase 8,650 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 2,275 shares"
Restricted stock units (RSUs) are a type of company promise to give employees shares of stock in the future, usually after certain conditions like working for a set time. They are like a gift promised today that you receive later, which can become valuable if the company's stock price goes up. RSUs matter because they are a way companies reward employees and can be a significant part of compensation.
nasdaq global marketfinancial
"The exercise price of the options is $122.58, which is equal to the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on June 30, 2026."
The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.
exercise pricefinancial
"The exercise price of the options is $122.58, which is equal to the per-share closing price"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
NEWARK, CA / ACCESS Newswire / July 1, 2026 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2026, it granted inducement awards to three recently hired employees in accordance with the terms of their employment offer letters. The awards were granted under the Protagonist Therapeutics Amended and Restated Inducement Plan, which was adopted May 29, 2018, and amended February 18, 2020 and February 15, 2022.
The new employees received, in the aggregate, options to purchase 8,650 shares of Protagonist Therapeutics common stock and restricted stock units (RSUs) to acquire 2,275 shares of Protagonist Therapeutics common stock. The exercise price of the options is $122.58, which is equal to the per-share closing price of Protagonist Therapeutics common stock on the Nasdaq Global Market on June 30, 2026. The shares subject to each option vest over a four-year period, with 25 percent of the shares subject to the option vesting on the first anniversary of each employee's date of hire and the remainder vesting in equal monthly installments over three years thereafter. One-fourth of the shares underlying the RSUs will vest annually over a four-year period. The awards were approved by the compensation committee of the Company's board of directors and were granted as a material inducement to each employee entering into employment with the Company in accordance with Nasdaq Marketplace Rule 5635(c)(4).
About Protagonist
Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company with a proprietary technology platform that enables de novo discovery of peptide therapeutics. Two novel peptides derived from Protagonist's proprietary discovery platform are at or near commercialization. ICOTYDE™ (icotrokinra), licensed to Johnson & Johnson company Janssen Biotech, Inc., is the first and only targeted oral peptide that precisely blocks the Interleukin-23 receptor. ICOTYDE was launched in the U.S. in March 2026, is approved for the treatment of moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years of age or older and is in Phase 3 development for psoriatic arthritis, ulcerative colitis and Crohn's disease. ICOTYDE was jointly discovered by Protagonist and Johnson & Johnson scientists, with Protagonist having primary responsibility for the development of ICOTYDE through Phase 1, and Johnson & Johnson assuming responsibility for further development and commercialization. Protagonist also discovered and led development through Phase 3 of rusfertide, a first-in-class hepcidin mimetic peptide licensed to Takeda Pharmaceuticals. An NDA for rusfertide for the treatment of polycythemia vera is under priority review with the FDA. The Company also has a number of clinical and preclinical programs addressing clinically and commercially validated targets, including an oral IL-17 antagonist peptide, obesity dual and triple agonists, an oral hepcidin functional mimetic, and the recently announced IL-4 and amylin programs.
More information on Protagonist, its pipeline drug candidates, and clinical studies can be found on the Company's website at https://www.protagonist-inc.com.
What inducement awards did Protagonist Therapeutics (PTGX) grant on June 30, 2026?
Protagonist Therapeutics granted stock options for 8,650 shares and 2,275 RSUs to three new employees. According to Protagonist Therapeutics, these awards were issued as material inducements to employment under the company’s Inducement Plan and Nasdaq Rule 5635(c)(4).
What is the exercise price of the new PTGX stock options granted on June 30, 2026?
The new PTGX stock options have an exercise price of $122.58 per share. According to Protagonist Therapeutics, this price equals the closing price of its common stock on the Nasdaq Global Market on June 30, 2026.
How do the PTGX inducement stock options granted in June 2026 vest?
The PTGX inducement stock options vest over four years. According to Protagonist Therapeutics, 25% of each grant vests on the first anniversary of hire, with the remaining 75% vesting in equal monthly installments over the following three years.
What is the vesting schedule for the Protagonist Therapeutics (PTGX) RSUs granted as inducement awards?
The RSUs granted by PTGX vest in four equal annual installments over four years. According to Protagonist Therapeutics, one-fourth of the shares underlying each RSU award vests each year, subject to continued employment with the company.
Why did Protagonist Therapeutics use Nasdaq Rule 5635(c)(4) for the June 2026 inducement grants?
Protagonist Therapeutics used Nasdaq Rule 5635(c)(4) to issue stock awards as material inducements to new hires. According to Protagonist Therapeutics, the compensation committee approved these non-plan grants specifically to support recruitment of three recently hired employees.
